Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / RIGHT 10/15/2029
-
Total 13F shares
-
14,151,554
-
Share change
-
+14,151,554
-
Total reported value
-
$2,529,405
-
Price per share
-
$0.13
-
Number of holders
-
19
-
Value change
-
+$2,529,386
-
Number of buys
-
19
Institutional Holders of Drugs Made In America Acquisition Corp. - RIGHT 10/15/2029 (DMAAR) as of Q1 2025
As of 31 Mar 2025,
Drugs Made In America Acquisition Corp. - RIGHT 10/15/2029 (DMAAR) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,151,554 shares.
The largest 10 holders included
Polar Asset Management Partners Inc., Hudson Bay Capital Management LP, Harraden Circle Investments, LLC, GLAZER CAPITAL, LLC, ARISTEIA CAPITAL, L.L.C., MANGROVE PARTNERS IM, LLC, Crossingbridge Advisors, LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, WOLVERINE ASSET MANAGEMENT LLC, and ATW SPAC MANAGEMENT LLC.
This page lists
19
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.